Study of the Therapeutic Effects of Cortical Autograft Implantation in Patients With Cerebral Ischemia

NCT ID: NCT04488965

Last Updated: 2020-11-03

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2025-09-01

Brief Summary

Brain lesions in the adult have dramatic consequences, because the spontaneous capacity of the brain to functionally recover is limited. Besides existing rehabilitative therapeutic approaches (e.g. physiotherapy), several lines of research aim at developing treatments to promote and refine brain plasticity to enhance functional recovery following brain injury.

This pilot clinical study aims at enrolling subjects victim of a stroke with neuronal destruction leading to a disabling motor deficit. Usually these patients benefit from intensive neurorehabilitation which allows them to progress up to a certain point but when their recovery plateau is reached; current medicine is disarmed and no effective treatment allows, to date, to improve further their performance. This monocentric pilot study aims at evaluating the feasibility and safety of Autologous Neural Cell Ecosystems (ANCE), which is a cortical autograft intended to be used on stroke patients, for the replacement of motor neurons destroyed during an ischemic stroke.

Detailed Description

Using neural grafts to restore function after lesions of the central nervous system is a challenging strategy. Most of the transplantation experience acquired the last decades was focused on fetal neuronal grafts. However, despite the great enthusiasm generated by this approach, ethical controversies, immune rejection, and lack of fetal donors remain a major problem. Therefore, autotransplantation of adult brain cells represents an attractive restoration alternative to bypass the caveats of fetal grafting.

The optimization of the procedure to obtain ANCE, a cortical autograft obtained from cortical biopsy, was first successfully demonstrated in producing long-term primary culture of adult human brain cells from temporal lobe tissues obtained from epilepsy and trauma neurosurgical patients. ANCE has been characterized as an ecosystem of autologous neural cells in suspension, composed of several cell types: astrocytes, proliferative progenitors and quiescent progenitors.

The production of ANCE has been implemented to prepare long-term primary culture from primate cortical biopsies. This allowed assessing the feasibility of autotransplantation from brain biopsy to reimplantation of cultured brain cells in a non-human primate model of motor cortex lesion. On the same model of cerebral cortex lesion in nonhuman primates, further study demonstrated, by quantitative behavioral evidence, the beneficial outcome of cell therapy following injury of the cerebral cortex.

Based on the encouraging results from past experiences on non-human primate model of motor cortex lesion, this monocentric pilot study aims at evaluating the feasibility and safety of ANCE (Autologous Neural Cell Ecosystems), which is cortical autograft intended to be used on stroke patients, for the replacement of motor neurons destroyed during an ischemic stroke.

Conditions

Ischemic Stroke

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Autologous neural cell ecosystems - ANCE

The patient will undergo first surgery under general anesthesia for the collection of the cortical biopsy (5x5x5 mm biopsy of non-dominant frontal cortex). After the production of ANCE from the cortical biopsy, which last 8 to 12 weeks, the patient will undergo a second neurosurgery, for the stereotaxic reimplantation of ANCE under general anesthesia.

Group Type: EXPERIMENTAL

Autologous transplant

Intervention Type: OTHER

Autologous transplant obtained from cortical biopsy

Interventions

Autologous transplant

Autologous transplant obtained from cortical biopsy

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

• Be between 18 and 75 years old.
• Victim of a first ischemic stroke in superficial Sylvian territory with at least frontal damage.
• Cerebral ischemic lesion demonstrated by MRI.
• Stroke older than one year.
• Presence of a motor hemi-syndrome with at least one involvement of the upper limb.
• Stable neurological deficit in motor function of the limb greater than two months apart before enrolling the patient in the study.
• Woman of childbearing potential with a negative blood pregnancy test before the biopsy and using a reliable method of contraception during the study.
• Patient capable of discernment and of giving informed consent himself.
• Absence of other serious pathologies or comorbidities.

Exclusion Criteria

• Brain lesions or a history of stroke or brain hemorrhage.
• Signs of peripheral neurological damage, such as radicular or trunk involvement
• History of spinal cord problems.
• History of neurosurgical intervention in the brain.
• surgical intervention contraindications.
• Anticoagulation, if it cannot be interrupted one week before and one week after each of the 2 brain surgeries.
• Coagulation disorders.
• Treatment of botulinum toxin during the last 3 months before inclusion.
• Seizures or anti-epileptic treatment.
• Global cognitive disorders, such as degenerative or vascular dementia.
• High blood pressure difficult to control.
• Alcohol or drug abuse.
• Known neoplasia.
• Inability to understand or cooperate in the study.
• MRI contraindication
• Pregnancy
• Penicillin intolerance or allergy

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire Vaudois

OTHER

Sponsor Role: lead

Responsible Party

Jocelyne Bloch

Associate professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Centre Hospitalier Universitaire Vaudois

Lausanne, Canton of Vaud, Switzerland

Countries

Switzerland

Central Contacts

Jocelyne Bloch, Pr MD

Role: CONTACT

jocelyne.bloch@chuv.ch

+41795562951

Facility Contacts

Jocelyne Bloch, MD

Role: primary

jocelyne.bloch@chuv.ch

+41 21 314 12 93

Other Identifiers

AVCell2020

Identifier Type: -

Identifier Source: org_study_id